KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Q3 2025 value amounting to $1.0 billion.

  • Jazz Pharmaceuticals' Accumulated Expenses rose 1665.29% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 1665.29%. This contributed to the annual value of $910.9 million for FY2024, which is 1474.13% up from last year.
  • According to the latest figures from Q3 2025, Jazz Pharmaceuticals' Accumulated Expenses is $1.0 billion, which was up 1665.29% from $874.8 million recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Accumulated Expenses peaked at $1.1 billion during Q1 2025, and registered a low of $374.0 million during Q1 2021.
  • In the last 5 years, Jazz Pharmaceuticals' Accumulated Expenses had a median value of $769.9 million in 2023 and averaged $749.3 million.
  • In the last 5 years, Jazz Pharmaceuticals' Accumulated Expenses skyrocketed by 11021.1% in 2021 and then tumbled by 116.29% in 2023.
  • Jazz Pharmaceuticals' Accumulated Expenses (Quarter) stood at $666.3 million in 2021, then grew by 20.55% to $803.3 million in 2022, then decreased by 1.16% to $793.9 million in 2023, then rose by 14.74% to $910.9 million in 2024, then grew by 9.95% to $1.0 billion in 2025.
  • Its Accumulated Expenses was $1.0 billion in Q3 2025, compared to $874.8 million in Q2 2025 and $1.1 billion in Q1 2025.